Montara Therapeutics, Inc.
Nadia Khan, PhD, is a seasoned scientist with extensive experience in neuroscience and gene therapy. Currently serving as a Senior Scientist at Montara Therapeutics, Inc. since January 2025, Nadia previously held similar roles at Deciduous Therapeutics and Mirimus. Expertise includes leading exploratory disease indication projects and conducting in-depth studies on gene therapy efficacy in vivo. At CODA Biotherapeutics, Nadia spearheaded critical in-life studies evaluating gene therapies using advanced models. Previous positions include Postdoctoral Researcher at the Icahn School of Medicine, where Nadia developed epilepsy models in mice, and a PhD in Cellular and Molecular Biology from the University of Wisconsin-Madison, focusing on the epigenetic mechanisms of epilepsy. Notable prior research includes contributing to AAV vector characterization and cancer biology studies during undergraduate and post-baccalaureate roles.
This person is not in any teams
Montara Therapeutics, Inc.
1 followers
We are Montara Therapeutics, a San Francisco–based precision-medicine neuroscience biotech startup. Our team boasts significant experience from successful biotech firms such as Mitokinin, Denali, and Soteria, supported by a world-class Scientific Advisory Board (SAB). We bring a new approach to tackling challenging established targets, along with unique experience in developing enzyme activators and domain expertise in mitophagy. Our mission is to create innovative therapies for diseases of the CNS, with a focus on precision medicine and genetically validated targets to enhance drug safety and efficacy.